New therapeutic options for lysosomal storage disorders: enzyme replacement, small molecules and gene therapy

By Beck Michael  

Human Genetics, Vol. 121, Iss. 1, 2007-03 ,pp. : 1-22

Springer Publishing Company

Access to resources Recommend Favorite

ER and oxidative stresses are common mediators of apoptosis in both neurodegenerative and non-neurodegenerative lysosomal storage disorders and are alleviated by chemical chaperones

By Wei Hui   Kim Sung-Jo   Zhang Zhongjian   Tsai Pei-Chih   Wisniewski Krystyna E.   Mukherjee Anil B.  

Human Molecular Genetics, Vol. 17, Iss. 4, 2008-02 ,pp. : 469-477

Oxford University Press

Access to resources Recommend Favorite

Multiplex Newborn Screening for Lysosomal Storage Disorders: Feasibility Is Growing but Prediction of Phenotype Needs Elucidation

By  

Public Health Genomics, Vol. 9, Iss. 4, 2006-09 ,pp. : 279-280

Karger

Access to resources Recommend Favorite

-Mannosidosis mice: a model for the human lysosomal storage disease

By Zhu Mei   Lovell Kathryn L.   Patterson Jon S.   Saunders Thomas L.   Hughes Elizabeth D.   Friderici Karen H.  

Human Molecular Genetics, Vol. 15, Iss. 3, 2006-02 ,pp. : 493-500

Oxford University Press

Access to resources Recommend Favorite

Systemic and neurologic abnormalities distinguish the lysosomal disorders sialidosis and galactosialidosis in mice

By de Geest N.   Bonten E.   Mann L.   de Sousa-Hitzler J.   Hahn C.   d'Azzo A.  

Human Molecular Genetics, Vol. 11, Iss. 12, 2002-06 ,pp. : 1455-1464

Oxford University Press

Access to resources Recommend Favorite